GlassScriptPhysician profile
Sundeep Viswanathan
NPI 1790947166
$21,239.89
in general payments reported to CMS, 2019-2025
35 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $354 · 2021: $52.34 · 2022: $1,903 · 2023: $1,773 · 2024: $1,573 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354 · Travel and Lodging: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.40 |
| Travel and Lodging | $670.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,031.52 | 2019 | |
| Heartflow, INC. | $2,101.19 | 2023-2025 | Ffrct |
| Boston Scientific Corporation | $1,516.35 | 2019-2022 | |
| Abbott Laboratories | $867.38 | 2020-2025 | Triclip, Mitraclip |
| Novartis Pharmaceuticals Corporation | $473.02 | 2019-2025 | |
| Medtronic Vascular, INC. | $383.12 | 2019 | |
| Impulse Dynamics (USA) INC. | $369.55 | 2022-2023 | Optimizer |
| Pfizer INC. | $234.39 | 2019-2025 | |
| Inari Medical, INC. | $215.17 | 2022 | |
| Cvrx, INC. | $209.33 | 2023-2025 | Barostim Neo System |
| Amgen INC. | $205.64 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $194.30 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $185.05 | 2024-2025 | Wegovy |
| Penumbra, INC. | $173.33 | 2025 | Indigo System |
| Medtronic, INC. | $172.55 | 2025 | Symplicity G3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $161.14 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Astellas Pharma US INC | $118.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $104.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.19 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $57.95 | 2020-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $57.79 | 2022 | |
| Abiomed | $53.28 | 2019-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $47.97 | 2025 | |
| Merck Sharp & Dohme LLC | $38.02 | 2024 | Verquvo |
| Baxter Healthcare | $30.43 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $28.39 | 2024 | Arcalyst |
| Genzyme Corporation | $25.21 | 2022 | |
| Bridgebio Pharma, INC. | $22.85 | 2025 | Attruby |
| Scpharmaceuticals INC. | $18.63 | 2025 | |
| Philips North America LLC | $16.28 | 2024 | (5091) Amb Mon & Diag Und |
| Lundbeck LLC | $13.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.90 | 2022 | |
| Akcea Therapeutics, INC. | $11.82 | 2019 | |
| Amarin Pharma, INC. | $10.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sundeep Viswanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.